FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 376 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 Tough questions for tough times in clinical research April 29, 2022 Load more HOT NEWS Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... What’s happened to cancer clinical trials during the COVID-19 pandemic? EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... Sun Safety
